1. S189: EARLY, DEEP, AND DURABLE RESPONSES, AND LOW RATES OF CRS WITH REGN5458, A BCMAXCD3 BISPECIFIC ANTIBODY, IN A PHASE 1/2 FIRST-IN-HUMAN STUDY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA. (23rd June 2022) Authors: Zonder, J. A.; Richter, J.; Bumma, N.; Brayer, J.; Hoffman, J. E.; Bensinger, W. I.; Wu, K. L.; Xu, L.; Chokshi, D.; Boyapati, A.; Cronier, D.; Houvras, Y.; Rodriguez Lorenc, K.; Kroog, G. S.; Dhodapkar, M. V.; Lentzsch, S.; Cooper, D.; Jagannath, S. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 90 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗